Rockwell Medical, Inc. (NASDAQ:RMTI) stock rose Tuesday after the company announced preliminary results for the three months and twelve months ended December 31, 2025.
The company said fourth-quarter sales are expected to total approximately $18.6 million, exceeding the Street consensus estimate of $16.55 million. Full-year revenue is projected to come in near $69.5 million.
The company expects the fourth-quarter 2025 gross margin to be approximately 22%, up from 14% in the third quarter 2025.
Management said the company also achieved adjusted EBITDA positivity and generated positive operating cash flow during the quarter.
Operating cash flow for the period totaled roughly $2.3 million. Rockwell Medical expects cash, cash equivalents, and available-for-sale investments to total about $25 million at year-end.
"Our preliminary financial results for the fourth quarter 2025 reflect our unrelenting drive towards making Rockwell Medical a profitable company and positioning the Company for long-term stability and success," said Mark Strobeck, Ph.D., president and chief executive officer.
Strobeck added that management plans to prioritize sales growth, improved profitability, and product diversification in 2026 as part of its longer-term strategy.
RMTI Price Action: Rockwell Medical shares were up 22.22% at $1.17 at the time of publication on Tuesday, according to Benzinga Pro data. The stock has lost over 56% in the past year.
Image via Shutterstock
